- Home
- HOWL vs ATOS Comparison
HOWL vs ATOS Comparison
Compare HOWL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | ATOS |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 36.2M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HOWL | ATOS |
|---|---|---|
| Price | $0.55 | $5.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 452.4K | 52.6K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.53 |
| 52 Week High | $2.23 | $7.56 |
Technical Indicators
Market Signals| Indicator | HOWL | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 44.30 |
| Support Level | N/A | $4.59 |
| Resistance Level | $0.74 | $6.18 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 13.45 | 15.11 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.